Anti-Prostate Cancer Drug Boosts Nymox Pharma (NYMX); Viveve Medical (VIVE) Moves Into Positive Territory

Nymox_ Pharmaceutical_NYMX

Shares of Nymox Pharmaceutical Corp. (Nasdaq:NYMX) continued an upward path for the second trading session in a row – reaching a new 52-week high of $5.79 in early trade Thursday -, following the positive momentum generated after the company said that a long-term prospective study on fexapotide (NX-1207) – its lead compound for an enlarged prostate (BPH) and prostate cancer – was successful.

According to Nymox, the trial data demonstrate that its fexapotide decreases the long-term need for surgery by 82% to 95% versus approved conventional BPH treatments and shows significant efficacy against prostate cancer as a therapeutic

NYMX stock is trading at $5.19, up $0.73 (or +16.48%) and 14.53M of its shares changde hands so far, representing a large increase in activity versus its average volum (3m) of 1.10M

Nymox Pharmaceutical, which engages in the research and development of drugs for the aging population, has 46.14M and NYMX stock new one-year range is between $1.62 and $5.79 per share



Viveve Medical Inc. (Nasdaq:VIVE) shares climbed more than 12% to touch the $9.20 mark in intraday trading Thursday, currently changing hands at $8.80, up $0.60 (or +7.32%)

There appears to be no confirmed news from the company driving the stock higher. A couple weeks ago, Viveve reported second quarter 2016 revenue of $1,556,000 versus revenue of $73,000 in the same period the prior year

Viveve Medical, which designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal laxity. has 10.61M and VIVE stock 52-week range is from $4.02 to $10.50 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at